August 18-20, 2020
Boston, MA

8:00 am Registration & Networking Coffee

8:50 am Chair’s Opening Remarks

• Chad May Senior Vice President - Research & Development, Maverick Therapeutics

Assessing Current Limitations of Cell Engagers including Strategies to Mitigate Toxicities to Ensure Patient Safety

9:00 am XTENylated Protease Activated T Cell Engagers: XPATS – A Novel Format to Mitigate the On-target, Off-tumor Problem

• Bryan Irving CSO, Amunix

9:30 am T Cell Engaging Antibody Circuits (TEAC): Focusing Immune Activation to the Cancer Cell Surface to Widen the Therapeutic Index

• Patricia Giblin VP of Biology, Revitope

10:00 am TriTACs Are T Cell Engaging Drugs for Treatment of Solid Tumors

• Rick Austin Senior Director of Biology Research, Harpoon

10:30 am The Promise of Vascularized Micro-Organs & Tumors for Drug Discovery

• Chris Hughes CSO, Aracari Biosciences

10:40 am Speed Networking & Morning Refreshments

11:30 am Advancing the Development of Protein-Based & Cellular Immunotherapies using Clinically-Validated, Scalable Electroporation

• James Brady VP of Technical Applications and Customer Support, MaxCyte

11:50 am Panel Discussion: Exploiting the High Protease Concentration in the Tumor Microenvironment to Reduce Toxicity

• Holger Wesche CSO, Harpoon Therapeutics Inc.
• Chad May Senior Vice President - Research & Development, Maverick Therapeutics
• Bryan Irving CSO, Amunix

12:30 pm Networking Lunch

Improving the Therapeutic Window of Cell Engagers: Addressing Half-Life and Cytokine Release Syndrome

1:30 pm Discovering and Designing the Next Generation of T cell Engagers

• Omid Vafa CBO, TeneoBio

2:00 pm Optimizing Therapeutic Index and Other Properties with Potency Reduction and Bivalent Target Engagement

• John Desjarlais CSO, Xencor

2:30 pm CB307: A Novel T cell Enhancing Humabody Bispecific

• James Legg SVP of Research, Crescendo Biologics

3:00 pm Afternoon Refreshments & Scientific Poster Session

Review of Current Clinical Data

4:00 pm Translating Preclinical BiTE® Data to the Clinic

• Julie Bailis Principal Scientist, Amgen

4:30 pm Flotetuzumab: An Experimental CD123 x CD3 Bispecific DART Molecule for the Treatment of AML

• Jan Davidson Director of Clinical Development & Research , Macrogenics

5:00 pm AMV564 Relieves Immune Suppression Through Selective Targeting of CD33

• Victoria Smith CSO, Amphivena

5:30 pm Chair’s Closing Remarks & End of Day One

• David DiLillo Associate Director, Immuno-Oncology, Regeneron